Combining multiple meds into a single pill reduces cardiovascular deaths

Image Credit: Copilot Dall e-3 AI generated.

Taking a single pill that combines medications targeting cardiovascular disease-related conditions was shown long ago to lower the risk of death from such causes, including heart attacks and strokes. The concept of using such “polypills” to prevent and treat atherosclerotic cardiovascular disease was introduced nearly 25 years ago. Shortly thereafter, the strategy was the focus of a seminal modeling study that promoted polypills to reduce cardiovascular disease at the population level. Still, many years and a body of supportive research later, use of such pills remains low throughout the world.

Now, a new study from researchers at Washington University School of Medicine in St. Louis bolsters previous findings and provides additional evidence that polypills are beneficial in preventing heart attacks and strokes and reducing deaths among people with cardiovascular risk factors, including high blood pressure and high cholesterol. As a result of the study, the World Health Organization (WHO) has added such polypills to its most recent Model List of Essential Medicines. The list comprises medicines considered key to public health due to their importance in treating common diseases, as well as their safety, efficacy and cost-effectiveness.

Rice biologists uncover new species of tiger beetle: Eunota houstoniana

Eunota houstoniana, with male on left and female on right.
Photo Credit: Rice University

Rice University evolutionary biologist Scott Egan and his research team have unearthed a new species of tiger beetle, deemed Eunota houstoniana, honoring the Houston region where it predominantly resides.

The team employed cutting-edge genetic sequencing technology alongside traditional measurements of their physical appearance and geographic range data to redefine species boundaries within the Eunota circumpicta species complex. This approach, known as integrative taxonomy, allowed them to identify distinct biological entities previously overlooked.

The study is published online in Nature Scientific Reports.

“It is amazing that within the city limits of Houston, we still don’t know all the species of insects or plants we share our region with,” Egan said. “I’m always interested in learning more about the biodiversity of the Gulf Coast.”

The Eunota houstoniana was once considered synonymous with the more common Eunota circumpicta, but the team’s research revealed significant differences, emphasizing the need for a refined process to species delineation.

Eunota houstoniana exhibits distinct genetic and physical characteristics. It is slightly smaller in size, its metallic coloring is more subdued, and it has unique behavior and habitat preferences.

Scientists identify Achilles heel of lung cancer protein

Researchers have shown for the first time that a crucial interface in a protein that drives cancer growth could act as a target for more effective treatments.

The study, led by the Science and Technology Facilities Council (STFC) Central Laser Facility (CLF) with support from the Imaging Therapies and Cancer Group at King's, used advanced laser imaging techniques to identify structural details of a mutated protein which help it to evade drugs that target it.

The study was published in the journal Nature Communications and lays the groundwork for future research into more effective, long-lasting cancer therapies.

The Epidermal Growth Factor Receptor (EGFR) is a protein that sits on the surface of cells and receives molecular signals that tell the cell to grow and divide. In certain types of cancer, mutated EGFR stimulate uncontrolled growth, resulting in tumors.

Various cancer treatments block and inhibit mutant EGFR to prevent tumor formation, but these are limited as eventually cancerous cells commonly develop further EGFR mutations that are resistant to treatment.

Until now, how exactly these drug-resistant EGFR mutations drive tumor growth was not understood, hindering our ability to develop treatments that target them.

Purdue researchers create biocompatible nanoparticles to enhance systemic delivery of cancer immunotherapy

Purdue University researchers are developing and validating patent-pending nanoparticles (left) to enhance immunotherapy effects against tumors. The nanoparticles are modified with adenosine triphosphate, or ATP, to recruit dendritic cells (right), which are immune cells that recognize tumor antigens and bring specialized immune cells to fight off tumors.
Image Credit: Yoon Yeo

Purdue University researchers are developing and validating patent-pending poly (lactic-co-glycolic acid), or PLGA, nanoparticles modified with adenosine triphosphate, or ATP, to enhance immunotherapy effects against malignant tumors.

The nanoparticles slowly release drugs that induce immunogenic cell death, or ICD, in tumors. ICD generates tumor antigens and other molecules to bring immune cells to a tumor’s microenvironment. The researchers have attached ATP to the nanoparticles, which also recruits immune cells to the tumor to initiate anti-tumor immune responses. 

Yoon Yeo leads a team of researchers from the College of Pharmacy, the Metabolite Profiling Facility in the Bindley Bioscience Center, and the Purdue Institute for Cancer Research to develop the nanoparticles. Yeo is the associate department head and Lillian Barboul Thomas Professor of Industrial and Molecular Pharmaceutics and Biomedical Engineering; she is also a member of the Purdue Institute for Drug Discovery and the Purdue Institute for Cancer Research.

The researchers validated their work using paclitaxel, a chemotherapy drug used to treat several types of cancers. They found that tumors grew slower in mice treated with paclitaxel enclosed within ATP-modified nanoparticles than in mice treated with paclitaxel in non-modified nanoparticles.

“When combined with an existing immunotherapy drug, the ATP-modified, paclitaxel-loaded nanoparticles eliminated tumors in mice and protected them from rechallenge with tumor cells,” Yeo said.

Researchers discover molecule that promotes production of cancer cells in triple-negative breast cancer

Hiroshima University researchers found that AIbZIP is highly upregulated in triple negative breast cancer (TNBC). AIbZIP induces hyper proliferation of TNBC cells by promoting the degradation of p27, a negative regulator for cell proliferation.
Illustration Credit: Atsushi Saito/Hiroshima University

A team of researchers from Hiroshima University has discovered a molecule that promotes the production of cancer cells. This molecule may prove to be a potential therapeutic target in the treatment of triple-negative breast cancer, an aggressive form of breast cancer.

Breast cancer is the most common type of cancer, ranking fifth among all cancers in cancer-related deaths. In 2020, there were 2.3 million new cases of breast cancer reported around the globe. In that year, breast cancer caused 685,000 deaths.

Several studies have reported that a molecule called AIbZIP (androgen induced basic leucine zipper) promotes malignant behavior in different cancer types. So, the research team examined the potential role of AIbZIP in malignant tumors. Their computer simulation analysis revealed that AIbZIP was highly expressed in the luminal androgen receptor subtype of triple negative breast cancer, playing a significant role in cell cycle regulation. They identified a novel mechanism by which AIbZIP regulates cancer cell proliferation in this type of breast cancer.

“We found that AIbZIP is highly upregulated in triple negative breast cancer. AIbZIP plays a crucial role for hyper proliferation of triple negative breast cancer cells by promoting the degradation of p27, a negative regulator for cell proliferation. Our study indicates that AIbZIP may be potential therapeutic target of triple negative breast cancer” said Atsushi Saito, an associate professor and Kazunori Imaizumi, a professor in the Department of Biochemistry, Graduate School of Biomedical and Health Sciences, Hiroshima University.  

Assessing the impact of sweeteners on appetite

Stevia
Photo Credit: Jan Haerer

Replacing sugar with artificial and natural sweeteners in foods does not make people hungrier – and also helps to reduce blood sugar levels, a significant new study has found. 

The double blind randomized controlled trial found that consuming food containing sweeteners produced a similar reduction in appetite sensations and appetite-related hormone responses as sugary foods - and provides some benefits such as lowering blood sugar, which may be particularly important in people at risk of developing type 2 diabetes. 

The use of sweeteners in place of sugar in foods can be controversial due to conflicting reports about their potential to increase appetite. Previous studies have been carried out but did not provide robust evidence. 

However, the researchers say their study, which meets the gold standard level of proof in scientific investigation, provides very strong evidence that sweeteners and sweetness enhancers do not negatively impact appetite and are beneficial for reducing sugar intake. The study is published in The Lancet eBioMedicine.  

Our study provides crucial evidence supporting the day-to-day use of sweeteners and sweetness enhancers for body weight and blood sugar control. 

‘Back to the Future’ to Forecast the Fate of a Dead Florida Coral Reef

Alex Modys, Ph.D., diving at the coral death assemblage in Pompano Ridge and digging up a subfossil coral, Orbicella annularis.
Photo Credit: Anton Olenik, Ph.D., Florida Atlantic University

Rising temperatures and disease outbreaks are decimating coral reefs throughout the tropics. Evidence suggests that higher latitude marine environments may provide crucial refuges for many at-risk, temperature-sensitive coral species. However, how coral populations expand into new areas and sustain themselves over time is constrained by the limited scope of modern observations. 

What can thousands of years of history tell us about what lies ahead for coral reef communities? A lot. In a new study, Florida Atlantic University researchers and collaborators provide geological insights into coral range expansions by reconstructing the composition of a Late Holocene-aged subfossil coral death assemblage in an unusual location in Southeast Florida and comparing it to modern reefs throughout the region. 

Located off one of the most densely populated and urbanized coastlines in the continental United States, the Late Holocene coral death assemblage known as “Pompano Ridge,” records a northward range expansion of tropical coral communities that occurred during a period of regional climate warming more than 2,000 years ago.

Could this happen again in the face of climate change? Going “back to the future,” this study offers a unique glimpse into what was once a vibrant coral reef assemblage and explores if history can repeat itself.

‘Exhausted’ immune cells in healthy women could be target for breast cancer prevention

Photo Credit: Angiola Harry

Everyone has BRCA1 and BRCA2 genes, but mutations in these genes - which can be inherited - increase the risk of breast and ovarian cancer.

The study found that the immune cells in breast tissue of healthy women carrying BRCA1 or BRCA2 gene mutations show signs of malfunction known as ‘exhaustion’. This suggests that the immune cells can’t clear out damaged breast cells, which can eventually develop into breast cancer.

This is the first time that ‘exhausted’ immune cells have been reported in non-cancerous breast tissues at such scale - normally these cells are only found in late-stage tumors.

The results raise the possibility of using existing immunotherapy drugs as early intervention to prevent breast cancer developing, in carriers of BRCA1 and BRCA2 gene mutations.

The researchers have received a ‘Biology to Prevention Award’ from Cancer Research UK to trial this preventative approach in mice. If effective, this will pave the way to a pilot clinical trial in women carrying BRCA gene mutations.

“Our results suggest that in carriers of BRCA mutations, the immune system is failing to kill off damaged breast cells - which in turn seem to be working to keep these immune cells at bay,” said Professor Walid Khaled in the University of Cambridge’s Department of Pharmacology and Wellcome-MRC Cambridge Stem Cell Institute, senior author of the report.

Magnetic Avalanche Triggered by Quantum Effects

Christopher Simon holds a crystal of lithium holmium yttrium fluoride.
Photo Credit: Lance Hayashida/Caltech

Iron screws and other so-called ferromagnetic materials are made up of atoms with electrons that act like little magnets. Normally, the orientations of the magnets are aligned within one region of the material but are not aligned from one region to the next. Think of groups of tourists in Times Square pointing to different billboards all around them. But when a magnetic field is applied, the orientations of the magnets, or spins, in the different regions line up and the material becomes fully magnetized. This would be like the packs of tourists all turning to point at the same sign.

The process of spins lining up, however, does not happen all at once. Rather, when the magnetic field is applied, different regions, or so-called domains, influence others nearby, and the changes spread across the material in a clumpy fashion. Scientists often compare this effect to an avalanche of snow, where one small lump of snow starts falling, pushing on other nearby lumps, until the entire mountainside of snow is tumbling down in the same direction.

Cats with MDR1 mutation at risk of severe reactions to popular medication

Photo Credit: Zhang Kaiyv

More than half a million cats in the United States could be at risk of a severe or even fatal neurological reaction to the active ingredient in some top-selling parasite preventatives for felines.

While the ingredient, eprinomectin, which is found in products like NexGard COMBO and Centragard, appears safe and effective for the significant majority of cats when used at label doses, a study conducted by Washington State University’s Program for Individualized Medicine identified a risk of severe adverse effects in cats with the MDR1 genetic mutation. Genetically affected cats lack a protective mechanism that prevents certain drugs, including eprinomectin, from entering the brain and causing serious neurological toxicity.

“Almost every week we receive reports about someone’s pet cat having serious reactions to eprinomectin. This is not an issue with the drug itself — the problem lies in the genes of 1% of cats. That is a sizable number considering there are over 60 million pet cats in the U.S., and we’re trying to increase general awareness of these risks,” said Dr. Katrina Mealey, a WSU veterinarian and pharmacologist who led the research.